Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

PHASE3CompletedINTERVENTIONAL
Enrollment

944

Participants

Timeline

Start Date

May 31, 2005

Study Completion Date

November 30, 2005

Conditions
MumpsVaricellaRubellaMeasles
Interventions
BIOLOGICAL

Measles, Mumps, Rubella and Chickenpox (live vaccine)

Trial Locations (85)

10315

GSK Investigational Site, Berlin

10967

GSK Investigational Site, Berlin

10999

GSK Investigational Site, Berlin

12627

GSK Investigational Site, Berlin

12679

GSK Investigational Site, Berlin

13055

GSK Investigational Site, Berlin

13355

GSK Investigational Site, Berlin

14197

GSK Investigational Site, Berlin

17192

GSK Investigational Site, Waren

18059

GSK Investigational Site, Rostock

18146

GSK Investigational Site, Rostock

18246

GSK Investigational Site, Bützow

22089

GSK Investigational Site, Hamburg

22143

GSK Investigational Site, Hamburg

22307

GSK Investigational Site, Hamburg

23879

GSK Investigational Site, Mölln

24534

GSK Investigational Site, Neumünster

24937

GSK Investigational Site, Flensburg

24943

GSK Investigational Site, Flensburg

24944

GSK Investigational Site, Flensburg

24955

GSK Investigational Site, Harrislee

25541

GSK Investigational Site, Brunsbüttel

25813

GSK Investigational Site, Husum

25821

GSK Investigational Site, Bredstedt

25899

GSK Investigational Site, Niebüll

32479

GSK Investigational Site, Hille

32549

GSK Investigational Site, Bad Oeynhausen

32756

GSK Investigational Site, Detmold

36037

GSK Investigational Site, Fulda

38226

GSK Investigational Site, Salzgitter

38302

GSK Investigational Site, Wolfenbüttel

40699

GSK Investigational Site, Erkrath

42579

GSK Investigational Site, Heiligenhaus

44866

GSK Investigational Site, Bochum

46145

GSK Investigational Site, Oberhausen

47533

GSK Investigational Site, Kleve-Materborn

47798

GSK Investigational Site, Krefeld

47877

GSK Investigational Site, Willich

54290

GSK Investigational Site, Trier

54294

GSK Investigational Site, Trier

54568

GSK Investigational Site, Gerolstein

55131

GSK Investigational Site, Mainz

55294

GSK Investigational Site, Bodenheim

55543

GSK Investigational Site, Bad Kreuznach

67059

GSK Investigational Site, Ludwigshafen am Rhein

67227

GSK Investigational Site, Frankenthal

67547

GSK Investigational Site, Worms

68161

GSK Investigational Site, Mannheim

68309

GSK Investigational Site, Mannheim

69214

GSK Investigational Site, Eppelheim

70469

GSK Investigational Site, Stuttgart

71634

GSK Investigational Site, Ludwigsburg

71672

GSK Investigational Site, Marbach

71720

GSK Investigational Site, Oberstenfeld

74357

GSK Investigational Site, Bönnigheim

74523

GSK Investigational Site, Schwäbisch Hall

75015

GSK Investigational Site, Bretten

76185

GSK Investigational Site, Karlsruhe

76327

GSK Investigational Site, Pfinztal

77654

GSK Investigational Site, Offenburg

77656

GSK Investigational Site, Offenburg

77694

GSK Investigational Site, Kehl

77704

GSK Investigational Site, Oberkirch

77955

GSK Investigational Site, Ettenheim

79199

GSK Investigational Site, Kirchzarten

79336

GSK Investigational Site, Herbolzheim

81241

GSK Investigational Site, Munich

86163

GSK Investigational Site, Augsburg

88069

GSK Investigational Site, Tettnang

88348

GSK Investigational Site, Bad Saulgau

89584

GSK Investigational Site, Ehingen

90473

GSK Investigational Site, Nuremberg

93426

GSK Investigational Site, Roding

95463

GSK Investigational Site, Bindlach

97828

GSK Investigational Site, Marktheidenfeld

97941

GSK Investigational Site, Tauberbischofsheim

98724

GSK Investigational Site, Neuhaus am Rennweg

99425

GSK Investigational Site, Weimar

01877

GSK Investigational Site, Bischofswerda

04720

GSK Investigational Site, Döbeln

01169

GSK Investigational Site, Dresden

04178

GSK Investigational Site, Leipzig

04317

GSK Investigational Site, Leipzig

09366

GSK Investigational Site, Stollberg

07356

GSK Investigational Site, Bad Lobenstein

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00127023 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases | Biotech Hunter | Biotech Hunter